Total US pharma industry M&A deals in Q4 2018 worth $11.95bn were announced, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 27.2% over the previous quarter and a drop of 22.6% when compared with the last four-quarter average of $15.43bn.

The United States held an 81.5% share of the global pharma industry M&A deal value that totalled $14.66bn in Q4 2018.

In terms of deal activity, the United States recorded 70 deals during Q4 2018, marking a rise of 6.1% over the previous quarter and a rise of 27.3% over the last four-quarter average.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US pharma industry M&A deals in Q4 2018: Top deals

The top five pharma industry M&A deals accounted for 90.4% of the overall value during Q4 2018.

The combined value of the top five pharma industry M&A deals stood at $10.8bn, against the overall value of $11.95bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.

In second place was the $2.1bn acquisition of Endocyte by Novartis and in third place was Swedish Orphan Biovitrum’s $1.97bn asset transaction with AstraZeneca.

The $1.2bn acquisition of Pacific Biosciences of California by Illumina and AMAG Pharmaceuticals and Magellan Merger Sub’s acquisition of Perosphere Pharmaceuticals for $433.2m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.